CJC-1295 PROTOCOL

Clinically Proven GH Stimulation - Long-acting secretagogue

Long-acting GHRH analog that amplifies endogenous GH signaling through sustained receptor binding (weekly dosing model).

What it is

CJC-1295 with DAC (Drug Affinity Complex) is a modified growth hormone–releasing hormone (GHRH) analog engineered to bind to albumin, dramatically extending its half-life. Unlike short-acting GHRH analogs (Sermorelin, CJC no-DAC), CJC-DAC maintains continuous stimulation of the pituitary GHRH receptor over multiple days.

Result: Elevates baseline IGF-1 and sustains GH signaling, supporting lean mass preservation, recovery, and connective tissue repair. This compound raises the entire GH operating range — not just the nightly pulse.
—without suppression, shutdown, or replacement.

Together:CJC-DAC binds to the GHRH receptor in the pituitary and stays there longer than native GHRH. Because of the DAC component, it attaches to albumin in circulation, extending activity from minutes to days

Growth hormone—activated, not replaced. It's not HGH. It's a signal, not a sledgehammer.

Axis: Growth Hormone (GH)

Mechanism: Pituitary GHRH receptor → downstream IGF-1 production

Vial Composition

Component	Amount
CJC-1952	10 mg
Total per vial	**10 mg**
Reconstitution: bacteriostatic water	2 mL
Final concentration: mg/mL (total peptide/ml)	5.0 mg/mL

Dosing Protocol

Parameter	Specification
Injection timing (PM for sleep | AM Fasted for Fat Loss)	Evening (PM)
Dose (total)	**1.0 mg**
CJC-1952	1.0 mg
Injection volume	0.2 mL (≈20 insulin units)
Frequency: days/week	1

Protocol Length

	Time Frame
Total duration: weeks	12
Active dosing days: days	12
Vials:	1.2

Supply Calculation

Item	Quantity
Total peptide required	12 mg
Vials required	2 vials (10 mg each)
Insulin syringes	12
BAC water	3 mL (recommended 1-10 mL vials

For educational and research reference only. Not intended for diagnosis, treatment, or medical advice.

CJC-1295 PROTOCOL NOTES

CJC-1295 (DAC) is a long-acting GHRH analog designed to elevate the growth hormone axis through sustained receptor stimulation rather than short, timed pulses. By binding to albumin via the DAC component, it maintains activity for up to a week, increasing overall GH exposure and raising downstream IGF-1 levels in a steady, predictable manner.

Clinically, this translates to improved recovery capacity, enhanced connective tissue resilience, lean mass preservation, and a more anabolic internal environment over time. Unlike nightly secretagogues that rely on sleep-timed pulses, CJC-DAC shifts the baseline upward — making it particularly useful in longer recomposition protocols, structured performance programs, or convenience-focused GH optimization strategies where consistency and compliance matter.